Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer
- PMID: 18307022
- DOI: 10.1007/s10147-007-0733-3
Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer
Abstract
Background: Hepatocellular cancer (HCC), as well as cholangiocellular cancer (CCC), has an extremely poor prognosis due to the extent of tumor at diagnosis and the underlying liver disease. Sirolimus is used in the transplantation setting as an immunosuppressive agent, but it also possesses antiproliferative and antiangiogenic properties. The objective of the study was to evaluate the effect of sirolimus on HCC and CCC.
Methods: In a prospective single-arm protocol, the tumor response to sirolimus as the primary endpoint was studied in 21 patients with advanced HCC and nine with CCC. Sirolimus was administered once daily by mouth, with the dose adjusted to a serum trough level between 4 and 15 mug/ml. Tumor response was evaluated by computed tomography (CT) or magnetic resonance imaging (MRI), according to the Response Evaluation Criteria in Solid Tumors (RECIST), every third month. Secondary measures were overall survival, time to tumor progression, tumor markers, and side effects.
Results: Of the patients with HCC, one had partial remission (PR) and fi ve patients had stable disease (SD) at 3 months. Of the patients with CCC, three had SD. The median survival for patients with HCC was 6.5 months (range, 0.2-36 months) and that for patients with CCC was 7 months (range, 2.6-35 months).
Conclusion: Treatment of HCC and CCC with sirolimus can induce temporary PD or SD. This pilot study indicates that sirolimus might be a promising drug for this treatment, but further clinical studies elucidating the biological effects are advocated.
Similar articles
-
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.BMC Cancer. 2010 May 11;10:190. doi: 10.1186/1471-2407-10-190. BMC Cancer. 2010. PMID: 20459775 Free PMC article. Clinical Trial.
-
The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.Oncol Rep. 2008 Oct;20(4):863-72. Oncol Rep. 2008. PMID: 18813828
-
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.Cancer. 2004 Aug 1;101(3):578-86. doi: 10.1002/cncr.20368. Cancer. 2004. PMID: 15274071
-
Management of combined hepatocellular and cholangiocarcinoma.Int J Clin Pract. 2008 Aug;62(8):1271-8. doi: 10.1111/j.1742-1241.2007.01694.x. Epub 2008 Feb 13. Int J Clin Pract. 2008. PMID: 18284443 Review.
-
Biomarkers for Hepatobiliary Cancers.Hepatology. 2021 Jan;73 Suppl 1:115-127. doi: 10.1002/hep.31175. Epub 2020 Nov 29. Hepatology. 2021. PMID: 32045030 Review.
Cited by
-
Insights in Molecular Therapies for Hepatocellular Carcinoma.Cancers (Basel). 2024 May 10;16(10):1831. doi: 10.3390/cancers16101831. Cancers (Basel). 2024. PMID: 38791911 Free PMC article. Review.
-
Immunosuppression in liver transplant oncology: position paper of the Italian Board of Experts in Liver Transplantation (I-BELT).Updates Surg. 2024 Jun;76(3):725-741. doi: 10.1007/s13304-024-01845-z. Epub 2024 May 7. Updates Surg. 2024. PMID: 38713396 Review.
-
Therapeutically targeting essential metabolites to improve immunometabolism manipulation after liver transplantation for hepatocellular carcinoma.Front Immunol. 2023 Jul 10;14:1211126. doi: 10.3389/fimmu.2023.1211126. eCollection 2023. Front Immunol. 2023. PMID: 37492564 Free PMC article. Review.
-
TMEM16A partners with mTOR to influence pathways of cell survival, proliferation, and migration in cholangiocarcinoma.Am J Physiol Gastrointest Liver Physiol. 2023 Aug 1;325(2):G122-G134. doi: 10.1152/ajpgi.00270.2022. Epub 2023 May 23. Am J Physiol Gastrointest Liver Physiol. 2023. PMID: 37219012 Free PMC article.
-
Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype.PLoS One. 2022 May 5;17(5):e0268073. doi: 10.1371/journal.pone.0268073. eCollection 2022. PLoS One. 2022. PMID: 35512017 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous